Innova Captab Ltd

Innova Captab Ltd

₹ 470 -0.51%
26 Apr - close price
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.

  • Market Cap 2,687 Cr.
  • Current Price 470
  • High / Low 590 / 443
  • Stock P/E 40.5
  • Book Value 67.9
  • Dividend Yield 0.00 %
  • ROCE 23.8 %
  • ROE 27.3 %
  • Face Value 10.0

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 30.1%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
242 242 233 283 302
211 208 202 242 258
Operating Profit 31 34 31 40 45
OPM % 13% 14% 13% 14% 15%
2 3 1 3 2
Interest 5 6 5 9 7
Depreciation 3 3 3 5 5
Profit before tax 25 28 25 30 35
Tax % 24% 31% 28% 24% 29%
19 20 18 23 25
EPS in Rs 3.91 4.08 3.66 4.77 4.39
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
356 373 411 801 926
315 322 356 704 813
Operating Profit 41 51 54 96 114
OPM % 11% 14% 13% 12% 12%
0 1 1 3 9
Interest 6 5 4 6 20
Depreciation 11 10 6 8 11
Profit before tax 25 38 46 86 92
Tax % 20% 26% 26% 25% 26%
20 28 34 64 68
EPS in Rs 165.67 232.42 287.50 532.92 14.16
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 35%
TTM: 16%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 33%
TTM: 4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 30%
Last Year: 27%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 12 12 12 12 48 48
Reserves 70 98 133 197 229 341
Preference Capital 0 0 0 0 47
72 54 46 199 190 520
68 81 179 167 238 265
Total Liabilities 223 245 370 575 704 1,173
78 73 79 183 183 352
CWIP 0 0 7 0 22 173
Investments 0 0 0 0 0 0
144 172 283 392 500 648
Total Assets 223 245 370 575 704 1,173

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
19 31 42 59 67
-9 -6 -20 -188 -91
-9 -23 -19 125 27
Net Cash Flow 1 1 3 -5 3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 93 85 123 97 104
Inventory Days 50 84 107 76 62
Days Payable 80 92 132 86 84
Cash Conversion Cycle 64 77 99 87 83
Working Capital Days 77 86 73 97 98
ROCE % 26% 28% 31% 24%

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024
50.90% 50.90%
3.57% 1.94%
10.31% 20.78%
35.22% 26.39%
No. of Shareholders 1,39,11739,396

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents